3月25日，港股上市的生物科技公司腾盛博药-B（02137）股价出现大幅下跌，盘中跌幅一度达到13.99%。截至发稿时，该股报2.52港元，跌幅为11.89%，成交额1683.76万港元。
此次股价大跌主要源于公司近日发布的2024年业绩报告。报告显示，腾盛博药全年亏损额为5.12亿元，同比扩大177.9%。值得注意的是，公司目前暂无产品实现商业化，收入主要来自银行利息和政府补助。2024年全年实现其他收入1.41亿元，同比减少13.6%。
回顾腾盛博药的发展历程，该公司曾在2021年成功研发出国内首款自主知识产权的新冠病毒中和抗体联合治疗药物——安巴韦单抗/罗米司韦单抗联合疗法。然而，这款药物在实现商业化后仅8个月就宣布停产。根据2022年年报披露的财务数据，该药物仅为公司带来5160万元的收入。这一系列因素可能导致投资者对公司未来盈利能力产生担忧，从而引发今日的股价大跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.